ArticleFrontiers in oncology2021
WHO Grade Loses Its Prognostic Value in Molecularly Defined Diffuse Lower-Grade Gliomas.
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- EANS-EANO guidelines on the extent of resection in gliomas.Neuro-oncology · 2026Guideline
- Frequency and Prognostic Impact of CDKN2A/B Alteration in Oligodendrogliomas: Systematic Review and Meta-analysis.Neurologia medico-chirurgica · 2024Pooled it
- Improving quality of care for patients with high-grade glioma and their informal caregivers: Insights from focus groups with healthcare professionals.Neuro-oncology practice · 2026Article
- Identifying clinically relevant cell state interactions in the tumor microenvironment of IDH-mutant gliomas using CSI-TME.Molecular systems biology · 2026Article
- Current and emerging therapies in IDH-mutant glioma.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Review
- Characteristics of [European journal of nuclear medicine and molecular imaging · 2026Article
- Lower-grade glioma imaging volumes and survival: a single-institution analysis of 90 patients after resection using intraoperative MRI.Journal of neuro-oncology · 2026Article
- Prognostic relevance of resection at first recurrence in isocitrate dehydrogenase mutant lower-grade glioma: results from a retrospective, single-center, volumetric analysis.Journal of neuro-oncology · 2026Observational
- Prognostic value of [European journal of nuclear medicine and molecular imaging · 2026Article
- Analysis of outcomes of patients with oligodendroglioma with focus on volumetric reduction.Neuro-oncology practice · 2025Article
- Evolutionary trajectories of IDH-mutant astrocytoma identify molecular grading markers related to cell cycling.Nature cancer · 2025Article
- Advances in IDH-mutant glioma management: IDH inhibitors, clinical implications of INDIGO trial, and future perspectives.Future oncology (London, England) · 2025Review
- Survival prediction with radiomics for patients with IDH mutated lower-grade glioma.Journal of neuro-oncology · 2025Article
- Reappraisal of prognostic factors in CNS WHO grade 3 oligodendrogliomas IDH-mutant and 1p/19q co-deleted: Lessons from the French POLA cohort.Neuro-oncology · 2025Article
- How to predict progression-free survival in patients with grade 2 IDH-mutated diffuse gliomas after surgery: a long-term follow-up analysis.Frontiers in oncology · 2025Article
- Diffusion MRI is superior to quantitative T2-FLAIR mismatch in predicting molecular subtypes of human non-enhancing gliomas.Neuroradiology · 2024Article
- The Role of Mutant IDH Inhibitors in the Treatment of Glioma.Current neurology and neuroscience reports · 2024Review
- Article
- The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?Neuro-oncology · 2024Review
- Differentiating IDH-mutant astrocytomas and 1p19q-codeleted oligodendrogliomas using DSC-PWI: high performance through cerebral blood volume and percentage of signal recovery percentiles.European radiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhile molecular insights to diffuse lower-grade glioma (dLGG) have improved the basis for prognostication, most established clinical prognostic factors come from the pre-molecular era. For instance, WHO grade as a predictor for survival in dLGG with MATERIAL AND
methodsA total of 253 adults with morphological dLGG, consecutively included between 2007 and 2018, were assessed.
resultsThere was no survival benefit for patients with WHO grade 2 over grade 3
conclusionOur findings suggest that WHO grade is not a robust prognostic factor in molecularly well-defined dLGG. Preoperative tumor size remained a prognostic factor in both
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.